Immunogenicity of Tumor Organoids derived from colorectal, gastric, gynaecological and non-small cell lung cancer, a Feasibility Study

Immunogenicity of Tumor Organoids derived from colorectal, gastric, gynaecological and non-small cell lung cancer, a Feasibility Study - Immunogenicity of Tumor Organoids

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55942

Enrollment

150

Registered

2014-04-11

Start date

2014-08-25

Completion date

Unknown

Last updated

2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer/bowel cancer gastric cancer non-small cell lung cancer/lung cancer Coloncancer, Lungcancer

Interventions

No intervention or diagnostic test is evaluated in this study. Pre-clinical research will be conducted on the blood and tumortissue of the participating patients.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: i. Patients with colorectal, gastric, gynaecological or non-small cell lung cancer ii. Undergoing a tumor biopsy or resection of the primary tumor/metastasis. With the exception of patients from whom tumor organoids cultures have been previously derived iii. Eligible for blood withdrawal of 80cc iv. Patients must have given written informed consent before any study specific procedures

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
Reactivity of autologous T cells primed with tumor organoids	—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Contacts

Public ContactE.E. Voest

Antoni van Leeuwenhoek (AVL)

e.voest@nki.nl020 – 5126273

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 21, 2026